Universität zu Köln

Babic, B., Fuchs, H. F. and Bruns, C. J. (2020). Neoadjuvant chemoradiotherapy or chemotherapy for locally advanced esophageal cancer? Chirurg, 91 (5). S. 379 - 384. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0385

Full text not available from this repository.

Abstract

Background According to international guidelines neoadjuvant chemoradiotherapy and chemotherapy are recommended for the treatment of locally advanced esophageal cancer. The treatment approach depends on the tumor entity (adenocarcinoma vs. squamous cell carcinoma). Objective What benefits do patients with locally advanced esophageal cancer have from neoadjuvant treatment? Is there information in the international literature on whether a particular neoadjuvant treatment is preferred? Does the type of neoadjuvant treatment depend on factors other than the tumor entity? Is there a standard in the drug composition of chemotherapy or a clearly defined chemoradiotherapy regimen? Material and methods A review, evaluation and critical analysis of the international literature were carried out. Results Patients with locally advanced esophageal cancer benefit from a neoadjuvant treatment. The current data situation for squamous cell carcinoma of the esophagus demonstrates a better response to neoadjuvant chemoradiotherapy compared to chemotherapy alone. Locally advanced adenocarcinoma of the esophagus can be treated with combined neoadjuvant chemoradiotherapy as well as by chemotherapy alone. Both lead to an improvement in the prognosis. There are often differences particularly among radiation treatment regimens in the different centers. Furthermore, the localization of the tumor can also be important for treatment decisions. Conclusion A neoadjuvant treatment is clearly recommended for locally advanced esophageal cancer. Currently, chemoradiotherapy according to the CROSS protocol is preferred for squamous cell carcinoma. For adenocarcinoma both chemotherapy according to the FLOT protocol as well as chemoradiotherapy in a neoadjuvant treatment concept lead to an improvement in the prognosis.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Babic, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Fuchs, H. F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bruns, C. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-335697
DOI:	10.1007/s00104-020-01150-6
Journal or Publication Title:	Chirurg
Volume:	91
Number:	5
Page Range:	S. 379 - 384
Date:	2020
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0385
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GASTROESOPHAGEAL ADENOCARCINOMA; PERIOPERATIVE CHEMOTHERAPY; RESECTABLE ESOPHAGEAL; PROGNOSTIC IMPACT; SURGERY; METAANALYSIS; MULTICENTER; SURVIVAL; FLUOROURACIL; OXALIPLATIN Multiple languages Surgery Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/33569